It could never be Allergan Eye Care. This deal was about aesthetics and that's why there is a HUGE difference in the experience the aesthetics people are having with AbbVie vs the sorry lot that was integrated into the AbbVie machine. This is most apparent on the Irvine site where you literally have 2 classes of employees. And among the legacy Allergan employees, arguably Eye Care is doing the worst now that all the CNS Forest expertise was shown the door.
Now here's the fun part - the truly dirty secret. Consistent with the AbbVie message board and the spot on comments regarding the stupidity of AbbVie management, the neurotoxin was aligned to aesthetics from an R&D perspective. The problem is the aesthetics people are filler and implant experts eg device not drugs but they are posing as drug developers since they won the integration lottery and believe they earned their luck. Kind of like everyone at AbbVie thinks they are the best at whatever and do not recognize the luck of having a cash cow like Humira.
Last I checked drug development is complex and very different that a hyaluronic filler. Many of the eye care experts R&D, Commercial, etc were experts across Eye Care and Toxins. Many of the most experienced legacy Allergan people were moved to Eye Care and are actively being pushed out with their institutional knowledge of Eye Care and Toxins out the door. Bottomline, the investment AbbVie made in toxins will go down the toilet like much of their investment in the legacy AbbVie TAs. The oncology pipeline is a thing a beauty.